FDA Issues Response Letter for Mirikizumab
The FDA cited manufacturing concerns in their letter for the potential ulcerative colitis treatment.
Stay updated with breaking news from Colitis Organization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA cited manufacturing concerns in their letter for the potential ulcerative colitis treatment.
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab)...
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to...
Patients with IBD who concurrently use cannabis show a highly significant reduction in inpatient mortality and hospital length of stay and around 25% drop in hospitalization costs.
Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib